Attached files
| file | filename |
|---|---|
| 8-K - CURRENT REPORT - NRX Pharmaceuticals, Inc. | brpa_8k.htm |
| EX-99.3 - PRESS RELEASE, DATED NOVEMBER 29, 2017 - NRX Pharmaceuticals, Inc. | brpa_ex993.htm |
| EX-99.1 - AUDITED BALANCE SHEET - NRX Pharmaceuticals, Inc. | brpa_ex991.htm |
Exhibit 99.2
BIG ROCK PARTNERS ACQUISITION CORP.
BALANCE SHEET
|
|
November
22,
|
Pro
Forma
|
|
|
|
2017
|
Adjustments
|
As
Adjusted
|
|
|
|
(unaudited)
|
(unaudited)
|
|
ASSETS
|
|
|
|
|
Current
assets
|
|
|
|
|
Cash
|
$741,476
|
$—
|
$741,476
|
|
Prepaid expenses
and other current assets
|
24,500
|
—
|
24,500
|
|
Total Current
Assets
|
765,976
|
—
|
765,976
|
|
|
|
|
|
|
Cash held in Trust
Account
|
60,000,000
|
9,000,000
|
69,000,000
|
|
Total
Assets
|
$60,765,976
|
$9,000,000
|
$69,765,976
|
|
|
|
|
|
|
LIABILITIES
AND STOCKHOLDERS' EQUITY
|
|
|
|
|
Current
liabilities
|
|
|
|
|
Accounts payable
and accrued expenses
|
$21,960
|
$—
|
$21,960
|
|
Accrued offering
costs
|
20,000
|
—
|
20,000
|
|
Promissory notes
– related parties
|
147,625
|
—
|
147,625
|
|
Total
Liabilities
|
189,585
|
—
|
189,585
|
|
|
|
|
|
|
Commitments
|
|
|
|
|
Common stock
subject to possible redemption, 5,557,639 and 6,457,639 shares at
redemption value
|
55,576,390
|
9,000,000
|
64,576,390
|
|
|
|
|
|
|
Stockholders'
Equity
|
|
|
|
|
Preferred stock,
$0.001 par value; 1,000,000 authorized; none issued and
outstanding
|
—
|
—
|
—
|
|
Common stock,
$0.001 par value; 100,000,000 shares authorized; 2,537,361 and
2,577,861 shares issued and outstanding (excluding 5,557,639 and
6,457,639 shares subject to possible redemption)
|
2,537
|
41
|
2,578
|
|
Additional paid-in
capital
|
4,998,754
|
(41)
|
4,998,713
|
|
Accumulated
deficit
|
(1,290)
|
—
|
(1,290)
|
|
Total
Stockholders' Equity
|
5,000,001
|
—
|
5,000,001
|
|
TOTAL
LIABILITIES AND STOCKHOLDERS' EQUITY
|
$60,765,976
|
$9,000,000
|
$69,765,976
|